Clinical UpdatesAPE1Chemoresistance
Therapeutic Reversal of SOX9-Mediated Chemoresistance in Esophageal Adenocarcinoma via APE1-Redox Inhibition
By MedXY|Mar 15, 2026
This review details a breakthrough in esophageal adenocarcinoma treatment, identifying the APE1-SOX9 axis as a primary driver of chemoresistance and demonstrating how targeting APE1’s redox function can sensitize tumors to oxaliplatin